1. Search Result
Search Result
Results for "

clots

" in MedChemExpress (MCE) Product Catalog:

60

Inhibitors & Agonists

1

Screening Libraries

4

Biochemical Assay Reagents

3

Peptides

7

Natural
Products

4

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W040030

    Others Metabolic Disease Cancer
    Hematin, an iron-containing porphyrin, inhibits the activity of clotting factors and also fibrin clot lysis through the mechanism of binding to and inactivation of hemostatic proteins . Hematin can be used for the research of acute porphyrias and cancer .
    Hematin
  • HY-125864

    Interleukin Related NF-κB Inflammation/Immunology
    Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .
    Fibrinogen (Bovine)
  • HY-B1560
    Bismuth subgallate
    1 Publications Verification

    Factor Xa Others
    Bismuth subgallate, a hemostatic agent, acts on coagulation factor XII (Hageman factor), leading to the activation of the coagulation cascade and improving early formation of a fibrin clot .
    Bismuth subgallate
  • HY-P2373
    Nattokinase, Natto fermentation
    1 Publications Verification

    Others Cardiovascular Disease
    Nattokinase, Natto fermentation is a potent fibrinolytic enzyme. Nattokinase can break down blood clots by directly hydrolyzing fibrin and plasmin substrate. Nattokinase can be used for the research of cardiovascular diseases .
    Nattokinase, Natto fermentation
  • HY-108883

    Fibrinolysins, Human plasma; Serum tryptase, Human plasma; TAL 05-00018, Human plasma

    Others Inflammation/Immunology
    Plasmin, Human plasma is an important protease present in blood that degrades many plasma proteins, including fibrin clots. Plasmin can also act as a potent regulator of the immune process and can directly interact with various cell types, including monocytes, macrophages, and dendritic cells .
    Plasmin, Human plasma
  • HY-P2824

    Others Cardiovascular Disease
    Streptokinase, β-hemolytic streptococcus (Lancefield Group C) is a bacteria-derived protein and a plasminogen activator. Streptokinase is widely used for the research of the blood-clotting disorders. Streptokinase improves reperfusion blood flow after coronary artery occlusion .
    Streptokinase, β-hemolytic streptococcus (Lancefield Group C)
  • HY-E70393A

    Others Metabolic Disease
    Human Factor IXa Beta is composed of two polypeptide chains held together by disulfide bonds. Human Factor IXa Beta shows clotting activity .
    Human Factor IXa Beta
  • HY-113164

    Endogenous Metabolite Others
    Vitamin K1 2,3-epoxide is an inactive metabolite form of Vitamin K1 (HY-N0684), which is reduced to active vitamin by microsomal epoxide reductase in the vitamin K epoxide cycle. Vitamin K1 2,3-epoxide is involved in blood clotting .
    Vitamin K1 2,3-epoxide
  • HY-109549

    CGP 39393; Revasc

    Thrombin Cardiovascular Disease
    Desirudin (CGP 39393) is a thrombin inhibitor. Desirudin can inhibit the formation of blood clots and venous stasis thrombosis, which is used for the research of thrombocytopenia or platelet dysfunction .
    Desirudin
  • HY-P4721

    Thrombin Cardiovascular Disease
    Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a KD < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM .
    Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated)
  • HY-B0236
    6-Aminocaproic acid
    2 Publications Verification

    EACA; Epsilon-Amino-n-caproic Acid; 6-Aminohexanoic acid

    Others Metabolic Disease Cancer
    6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .
    6-Aminocaproic acid
  • HY-118284
    Vicagrel
    1 Publications Verification

    P2Y Receptor Cardiovascular Disease
    Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease .
    Vicagrel
  • HY-17459
    Clopidogrel hydrogen sulfate
    Maximum Cited Publications
    21 Publications Verification

    (S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate

    Cytochrome P450 P2Y Receptor Cardiovascular Disease Cancer
    Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation .Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
    Clopidogrel hydrogen sulfate
  • HY-156023

    Sirtuin Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Sirtuin modulator 7 is a sirtuin-modulating compound which may increase the lifespan of a cell, and may be used for research of diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and flushing which would benefit from increased mitochondrial activity .
    Sirtuin modulator 7
  • HY-E70393H

    Others Others
    Human Factor XIIIa is a transglutaminase, which catalyzes the cross-linking of proteins and stabilizes the blood clots. Human Factor XIIIa protects the clots from degradation by fibrinolytic enzymes, which is important for maintaining hemostasis and preventing excessive bleeding .
    Human Factor XIIIa
  • HY-148322

    Sirtuin Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Sirtuin modulator 5 is a sirtuin modulating agent. Sirtuin modulator 5 can activate SIRT1 with a DC50 value of <50 μM. Sirtuin modulator 5 can be used for increasing the lifespan of a cell and used for the research of variety of diseases including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity .
    Sirtuin modulator 5
  • HY-B2172

    Endogenous Metabolite Cardiovascular Disease
    Vitamin K, the blood-clotting vitamin, is important for the function of numerous proteins within the body, such as the coagulation factors, osteocalcin and matrix-Gla protein.
    Vitamin K
  • HY-153480

    BAX499

    Factor Xa Others
    ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
    ARC19499
  • HY-153480A

    BAX499 sodium

    Factor Xa Factor VIIa Others
    ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
    ARC19499 sodium
  • HY-B0665

    Others Cardiovascular Disease Cancer
    Fibrin, isolated from bovine blood, is an insoluble protein produced in response to bleeding. Fibrin is the major component of the blood clot and is used for coagulation .
    Fibrin
  • HY-120491

    Others Cardiovascular Disease
    L 722151 is a competitive inhibitor for factor XIIIa with Ki of 49 µM. L 722151 accelerates tissue plasminogen activator-catalyzed clot dissolution, and exhibits antithrombotic efficacy .
    L 722151
  • HY-147393

    Others Cardiovascular Disease
    Factor VII-IN-1 (example 43) is a potent inhibitor of factor VII (FVII), with an IC50 of 1.1 μM. Factor VII-IN-1 shows anticoagulant properties .
    Factor VII-IN-1
  • HY-15283
    Clopidogrel
    Maximum Cited Publications
    21 Publications Verification

    Clopidogrelum

    P2Y Receptor Cardiovascular Disease Cancer
    Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
    Clopidogrel
  • HY-B1181

    Others Cardiovascular Disease
    Hydrastinine hydrochloride is a major alkaloid constituent in goldenseal (Hydrastis canadensis). Hydrastinine hydrochloride can be used as a haemostatic agent .
    Hydrastinine hydrochloride
  • HY-B1181A

    Others Cardiovascular Disease
    Hydrastinine is a major alkaloid constituent in goldenseal (Hydrastis canadensis). Hydrastinine can be used as a haemostatic agent .
    Hydrastinine
  • HY-120980

    TXB1

    Prostaglandin Receptor Cardiovascular Disease
    Thromboxane B1 (TXB1) is one of thromboxane B (TXB) family members. Thromboxane is a member of the family of lipids known as eicosanoids. Thromboxane is named for its role in blood clot formation (thrombosis) .
    Thromboxane B1
  • HY-E70393D

    Others Others
    Human Factor Alpha XIIa is a blood coagulation protease, which increases the clotting potential. Human Factor Alpha XIIa exhibits a fibrinolysis protein homologous heavy chain, indicating its function in fibrinolysis .
    Human Factor Alpha XIIa
  • HY-117724

    PAI-1 Cardiovascular Disease
    AZ3976 is a potent plasminogen activator inhibitor type 1 (PAI-1) inhibitor with an IC50 value of 26 μM in an enzymatic chromogenic assay. AZ3976 is active with an IC50 of 16 μM in a plasma clot lysis assay. AZ3976 does not bind to active PAI-1 but bound reversibly to latent PAI-1. AZ3976 inhibits PAI-1 by enhancing the latency transition of active PAI-1. AZ3976 displays profibrinolytic activities in a human plasma clot lysis assay .
    AZ3976
  • HY-14854

    ATI-5923

    Others Cardiovascular Disease
    Tecarfarin (ATI-5923) is an orally active and non-competitive vitamin K epoxide reductase (VKOR) antagonist, and impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X . Tecarfarin has the antithrombotic activity .
    Tecarfarin
  • HY-10787
    Ximelagatran
    1 Publications Verification

    H 376/95

    Thrombin Cardiovascular Disease
    Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics .
    Ximelagatran
  • HY-14854A

    ATI-5923 sodium

    Others Metabolic Disease
    Tecarfarin sodium (ATI-5923 sodium) is a novel orally active non-competitive vitamin K epoxide reductase (VKOR) antagonist, impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X . Tecarfarin sodium has the antithrombotic activity .
    Tecarfarin sodium
  • HY-15283R

    P2Y Receptor Cardiovascular Disease Cancer
    Clopidogrel (Standard) is the analytical standard of Clopidogrel. This product is intended for research and analytical applications. Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
    Clopidogrel (Standard)
  • HY-107966

    Nadroparin calcium (MW 15000-19000)

    Thrombin Factor Xa Autophagy Bacterial Cardiovascular Disease Cancer
    Heparin calcium (MW 15000-19000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .
    Heparin calcium (MW 15000-19000)
  • HY-107966A

    Nadroparin calcium (MW 3600-5000)

    Thrombin Factor Xa Autophagy Bacterial Cardiovascular Disease Cancer
    Heparin (Nadroparin) calcium (MW 3600-5000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .
    Heparin calcium (MW 3600-5000)
  • HY-12586

    Others Others
    AZD6564 is an orally active inhibitor for fibrinolysis through disruption of plasma kinase-fibrin interaction. AZD6564 dissolves human plasma clot with an IC50 of 0.44 μM. AZD6564 ameliorates hemorrhage in rats with EC50 of 1.62 μM, and exhibits good pharmacokinetic characteristics in rats .
    AZD6564
  • HY-124577

    PAI-1 Cardiovascular Disease
    MDI-2268 is an inhibitor of plasma kallikrein inhibitor 1 (PAI-1). MDI-2268 has good antithrombotic properties and regulates blood coagulation and fibrinolysis process by enhancing fibrinolysis. MDI-2268 can be used in research areas such as deep vein thrombosis .
    MDI-2268
  • HY-130587

    Piperazine sultosylate; A-585

    Others Metabolic Disease
    Sultosilic acid piperazine salt (Piperazine sultosylate; A-585) is a lipid-lowering agent. Sultosilic acid piperazine salt modifies the blood lipids levels, reduces platelet adhesiveness without promoting peroxisomal activity of hepatocytes or producing other adverse side-effects .
    Sultosilic acid piperazine salt
  • HY-E70393

    Factor VIIa Others
    Human Factor VIIa is a vitamin K-dependent serine protease that is involved in the blood coagulation process. Human Factor VIIa activates Factor X, which causes the conversion of prothrombin to thrombin and the conversion of fibrinogen to fibrin, leading to the formation of blood clots. Human Factor VIIa exhibits the potential to ameliorate Hemophilia .
    Human Factor VIIa
  • HY-117290

    Factor Xa Cardiovascular Disease
    BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor . BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial thromboplastin time, and decreases exposure dependently in FXI clotting activity .
    BMS-962212
  • HY-19517

    Others Cardiovascular Disease
    R1663 is a factor Xa inhibitor with anticoagulant activity. R1663 does not affect bleeding time. The pharmacodynamic effects (such as inhibition of thrombin generation) and plasma concentrations of R1663 are dose-dependent. R1663 prolongs clotting time in a concentration-dependent manner and inhibits the peak height of thrombin generation and endogenous thrombin potential .
    R1663
  • HY-B0236A

    EACA hydrochloride; Epsilon-Amino-n-caproic Acid hydrochloride; 6-Aminohexanoic acid hydrochloride

    Others Metabolic Disease Cancer
    6-Aminocaproic acid hydrochloride, a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .
    6-Aminocaproic acid hydrochloride
  • HY-E70393E

    Others Others
    Human Factor XIIa Beta is the active fragment of coagulation factor XII, that participates in the intrinsic pathway of coagulation, and leads to the formation of blood clots. Human Factor XIIa Beta also participates in the kinin-generating pathway, which leads to the release of bradykinin (vasodilator). Human Factor XIIa Beta stimulates the release of catecholamines, and mediates its cardiovascular effects through a noncholinergic angiotensin-converting enzyme (ACE)-regulated mechanism .
    Human Factor XIIa Beta
  • HY-50667R

    Factor Xa Cardiovascular Disease Cancer
    Apixaban (Standard) is the analytical standard of Apixaban. This product is intended for research and analytical applications. Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .
    Apixaban (Standard)
  • HY-50667
    Apixaban
    5+ Cited Publications

    BMS-562247-01

    Factor Xa Cardiovascular Disease Cancer
    Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .
    Apixaban
  • HY-50667S

    BMS-562247-01-13C,d3

    Factor Xa Cardiovascular Disease
    Apixaban- 13C,d3 is a deuterium and 13C labeled Apixaban. Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively[1].
    Apixaban-13C,d3
  • HY-N7314

    Syk Inflammation/Immunology
    Asebogenin has antimalarial activity in vitro . Asebogenin can inhibit the phosphorylation of Syk, thereby effectively suppressing platelet activation and the formation of neutrophil extracellular traps .
    Asebogenin
  • HY-113958

    LM-2219

    Others Others
    Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
    Difethialone
  • HY-113958R

    Others Others
    Difethialone (Standard) is the analytical standard of Difethialone. This product is intended for research and analytical applications. Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
    Difethialone (Standard)
  • HY-B0236S1

    EACA-d10; Epsilon-Amino-n-caproic Acid-d10; 6-Aminohexanoic acid-d10

    Isotope-Labeled Compounds Metabolic Disease
    6-Aminocaproic acid-d10 is the deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].
    6-Aminocaproic acid-d10
  • HY-B0236S

    EACA-d6; Epsilon-Amino-n-caproic acid-d6; 6-Aminohexanoic acid-d6

    Isotope-Labeled Compounds Metabolic Disease
    6-Aminocaproic acid-d6 is deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].
    6-Aminocaproic acid-d6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: